“…Most importantly, the N170 does not consistently categorize individuals and does not measure a specific impairment (facial expression processing) related to a specific clinical profile (e.g., ASD). Moreover, disentangling the specific neural response to the facial expression from the general neural face processing response is challenging, especially since deficits in general (neutral) face processing have also been reported in both ASD (177,189) and primary psychosis (64,145,179). Accordingly, and in spite of many studies claiming otherwise [e.g., (58,61)], it is highly questionable whether the N170 may ever fulfill its promise of being a sensitive biomarker for aberrant socioemotional sensitivity and definitely not for disorder-specific dysfunction [e.g., (121,185,190)].…”